Evaluation of Teclistamab in RRMM Patients Following Exposure to Other BCMA-Targeted Agents Presented at EHA 2022

Dr. Cyrille Touzeau Discusses Evaluation of Teclistamab in RRMM Patients Following Exposure to Other BCMA-Targeted Agents

Abstract Title:

Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Following Exposure to Other B-Cell Maturation Antigen (BCMA)-Targeted Agents

What is the purpose of this trial? 

Teclistamab (JNJ-64007957) is a T cell redirecting bispecific antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to induce T cell mediated cytotoxicity of BCMA-expressing myeloma cells. MajesTEC-1 is an open-label, multicohort, phase 1/2 study evaluating teclistamab in patients with relapsed/ refractory multiple myeloma (RRMM) previously treated with ≥3 prior lines of therapy (LOT). An overall response rate (ORR) of 62.0% in patients with no prior anti-BCMA treatment (tx) was previously reported in a pooled analysis from phase 1 and phase 2 cohort A at a median follow-up (MFU) of 7.8 months.

Here, efficacy and safety results of teclistamab from cohort C are reported, which enrolled patients who had prior exposure to anti-BCMA treatment.

In this video:

Dr. Cyrille Touzeau (University Hospital of Nantes—Nantes, France) reports on the evaluation of teclistamab’s (JNJ-64007957) safety and efficacy in RRMM Patients following exposure to other BCMA-targeted agents.

Conclusion:

These preliminary results observed with serial targeting of BCMA with teclistamab following Antibody-drug conjugates (ADC) or CAR T treatment (tx) suggest a promising overall response rate (ORR) with early responses that deepen over time. Additionally, a well-tolerated safety profile was observed in patients treated with anti-BCMA tx.